AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04022694 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exposure to beverage calorie information
Description: Calories for sugar-sweetened and non-sugar-sweetened beverages
Study NCT04022694 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure to beverage calorie information
Description: Calories for sugar-sweetened and non-sugar-sweetened beverages
Study NCT00884988 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lymphomyosot
Description: 20 drops X3/day, until discharge
Study NCT00884988 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo remedy
Description: 20 drops X3/day, until discharge
Study NCT00738088 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gliclazide
Description: Gliclazide 80mg bd for 6 weeks
Study NCT01685554 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: hypothermic CPB
Description: maintenance of mild hypothermia during cardiopulmonary bypass
Study NCT01685554 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: normothermic CPB
Description: maintenance of normal body temperature during cardiopulmonary bypass
Study NCT02957448 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS 986141
Description: Two single doses BMS 986141 (days 1 and 13) and single daily doses Rifampin (days 7-22)
Study NCT03050125 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Iso-osmolar drop
Description: 300 mOsmol sterile saline drops used as a contact lens rewetting drop.
Study NCT04224363 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: staining from cervical esophagus to esophagogastric junction
Description: This group patients were given Lugol's solution staining from cervical esophagus to esophagogastric junction （downward）during chromemdoscopy.
Study NCT04224363 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: staining from esophagogastric junction to cervical esophagus
Description: This group patients were given Lugol's solution staining from esophagogastric junction to cervical esophagus（upward）during chromemdoscopy.
Study NCT01724281 — intervention group
Intervention type: OTHER
Intervention: No intervention, only follow up
Study NCT02957448 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin
Description: Two single doses BMS 986141 (days 1 and 13) and single daily doses Rifampin (days 7-22)
Study NCT00031993 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib hydrochloride
Description: Given PO
Study NCT00031993 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT04542564 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: telemedicine
Description: a mobile app and telemedicine platform to confirm good blood pressure control and may save doctor face-to-face consultation
Study NCT04542564 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: usual care
Description: These patients have unrestricted access to healthcare resources such as general outpatient clinics and emergency departments
Study NCT04542564 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: usual care
Description: These patients have unrestricted access to healthcare resources such as general outpatient clinics and emergency departments
Study NCT01251679 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hand washing
Description: hand washing education and material
Study NCT01251679 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hand washing and surgical mask
Description: hand washing education and material and paper surgical face masks
Study NCT00601978 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: carbidopa/levodopa
Study NCT02800252 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One-stage full-mouth periodontal ultrasonic debridement plus placebo intervention
Study NCT02800252 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 3g omega-3 plus 100mg aspirin daily for 60 days
Description: Full-mouth periodontal debridement, 3g omega-3 plus 100mg aspirin daily for 60 days after periodontal therapy
Study NCT00601978 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carbidopa/Levodopa/Entacapone
Study NCT03916068 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hyperbaric Oxygen Therapy
Description: Hyperbaric oxygen therapy at 2.4 atmospheres for 90 minutes for 30 sessions.
Study NCT03916068 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trental Pill
Description: Trental 400 mg three times daily, in combination with Vitamin E 400 IU twice daily
Study NCT03916068 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin E
Description: Vitamin E 400 IU twice daily, in combination with Trental 400 mg three times daily
Study NCT02591615 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MK-3475
Description: Dose frequency of Q3W, Day 1 of each cycle
Study NCT02591615 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Dose frequency of Q3W, Day 1 of each cycle (standard Chemotherapy)
Study NCT02591615 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Dose frequency of Q3W, Day 1 of each cycle (standard Chemotherapy)
Study NCT02591615 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: Dose frequency of Q3W, Day 1 of each cycle (standard Chemotherapy)
Study NCT03898570 — intervention group
Intervention type: BEHAVIORAL
Intervention: Patient reported outcomes
Description: Patients will download the research app onto their phone and enter pertinent medical history and surgical history data similar to standard registries for specific procedures. Over the next 12 months the investigators will obtain patient-reported outcomes (PROs) using the patient's phone.~Specifically, the investigators will obtain daily activity data, weekly 6-minute-walk tests, and quarterly quality of life surveys
Study NCT03783195 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sugar drink
Description: A sugar drink made with 1.2 g/kg body weight of added sugar( 0.75g/kg body weight of fructose + 0.45g/kg body weight of glucose) and 24oz water
Study NCT03884686 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Web-based education resource
Description: Intervention includes fact sheets, question and answers, short videos featuring patients and/or clinicians.
Study NCT02249741 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treated with Ibandronic acid as per protocol
Description: treated with Ibandronic acid at a dose of 150 mg once a month for six months
Study NCT04489654 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: deproteinized bovine bone mineral (DBBM) by OneXeno Graft. ( OneGraft, Germany)
Description: deproteinized bovine bone mineral (DBBM) put in the gap between implant and labial shield
Study NCT00907075 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: NES With Energy Restriction
Description: The NES will be administered based upon the individual's calculated daily energy requirement, with an energy deficit of approximately 500 kilocalories.
Study NCT00907075 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: NES Without Energy Restriction
Description: The NES will be administered based upon the individual's calculated daily energy requirement.
Study NCT04116021 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PECS block
Description: Ultrasound-guided PECS block before surgical incision with 30 mL bupivacaine 0.5 %
Study NCT04116021 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Local infiltration
Description: Wound infiltration at the end of surgery with with 30 mL bupivacaine 0.5 %
Study NCT04790942 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: berberine hydrochloride
Description: the berberine hydrochloride group (BBR) take berberine hydrochloride tablets (0.4g, 3 times/day, 3 months)
Study NCT04790942 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: lifestyle intervention group
Description: The lifestyle intervention group (CON) mainly includes reducing sodium intake, healthy diet guidance, increasing exercise, quitting smoking and restricting alcohol consumption
Study NCT02369783 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire and interview
Description: The aim is to detect social fragility.
Study NCT04239417 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Graduated abdominal strengthening exercises
Description: 1. Exercise mat and inflatable Swiss ball~2. Wall bar, wedges, elastic tubing
Study NCT04239417 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Russian current stimulation
Description: The Russian current is used for enhancing muscle; the muscular fiber by the electric stimulation.
Study NCT04239417 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Graduated abdominal strengthening exercises and the Russian current stimulation
Description: Combination between The Russian current and abdominal exercises
Study NCT04627740 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Retroviral vector-transduced autologous T cells to express anti-ALPP CARs
Description: Cyclophosphamide will be administered at dose of 20mg/kg for 1 day and then fludarabine will be given for the next 3 days with 35mg/m2 and then the CAR-T cells will be administered
Study NCT00626873 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Definity
Description: Definity - perflutren lipid microspheres, 1-10 microns in diameter, which is approved for the use in patients with suboptimal echocardiograms to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border, to enhance the visualization of the ovarian vascular system.
Study NCT00626873 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: medical chart review
Study NCT01903876 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bystander & Sexual Violence Prevention
Description: This 3-hour web-based program consists of six 30-minute modules that are interactive and range in number of segments (1-14) and types of activities. Each of the modules involves interactivity, didactic activities and two episodes of a serial drama, which allows for the modeling of positive behaviors and illustrate both positive and negative outcome expectations for intervening and for perpetrating abuse against women. Behaviors modeled include communicating with female sex partners, obtaining informed consent to have sex, and intervening to prevent abuse from taking place.
Study NCT01903876 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: General Health Promotion
Description: This general health promotion web-based program is 3-hours and provides a range of activities related to reducing day-to day stress and alleviating anxiety through meditation and exercise.
Study NCT03231514 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Carbohydrate Supplement (Carb10)
Description: 2 of 4 arms will be supplemented with carbohydrate pre-workout (Carb10, Compound Solutions, Carlsbad, CA)
Study NCT03231514 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Carbohydrate Supplement (Carb10)
Description: 2 of 4 arms will be supplemented with carbohydrate pre-workout (Carb10, Compound Solutions, Carlsbad, CA)
Study NCT03231514 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet
Description: 2 groups will be on a carbohydrate-based diet (% energy from carbohydrate:fat:protein, 53:24:23) and 2 groups will be on a ketogenic diet (72:5:23)
Study NCT03231514 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: All groups will participate in a standardized exercise intervention.
Study NCT03231514 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Exercise
Description: All groups will participate in a standardized exercise intervention.
Study NCT03231514 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: All groups will participate in a standardized exercise intervention.
Study NCT05553743 — intervention group
Intervention type: DRUG
Intervention: Antibiotic
Description: Have or have not been prescribed one of several commonly used antibiotics including azithromycin, amoxicillin and clavulanic acid, amoxicillin, or nitrofurantoin.
Study NCT02728674 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Symptom in the case is pain.
Description: Symptom in the case is pain.
Study NCT01996527 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3-Tesla magnetic resonance imaging
Description: 3-Tesla MRI is a multiparametric imaging exam that includes MR pulse sequences for CEST-MRI, DW-MRI, DCE-MRI, and DSC-MRI
Study NCT01996527 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CEST-MRI
Description: Undergo CEST-MRI
Study NCT01996527 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DW-MRI
Description: Undergo DWI-MRI
Study NCT01996527 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DCE-MRI
Description: Undergo DCE-MRI
Study NCT01996527 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DSC-MRI
Description: Undergo DSC-MRI
Study NCT01996527 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV administration of gadolinium-containing contrast agent
Description: Gadolinium-containing paramagnetic contrast agent (Magnevist®; Berlex Lab, Wayne, New Jersey) in delivered via intravenous (IV) infusion to achieve DCE and DSC contrast
Study NCT01887652 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional ovarian stimulation
Description: a protocol of ovarian stimulation with recombinant FSH with dose according to age, ovarian size and previous treatment. In patients alder than 35, recombinant LH was added to ovarian stimulation.
Study NCT01887652 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: individualized ovarian stimulation
Description: After defining cut-off points of anti-mullerian hormone, using a ROC analysis, to discriminate excessive (≥20 oocytes retrieved) and poor response (≤4 oocytes retrieved), a individualized protocol was defined.Mild stimulation using daily doses (112.5 to 150 IU) of recombinant FSH or recombinant FSH combined with recombinant LH supplementation (375 IU total daily dose) were given to patients identified as at risk of excessive and poor response.
Study NCT02432976 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide
Description: Exenatide. Exenatide: bolus of 0.05 µg/min infused during the 1st hour of treatment, followed by a continuous infusion of 0.025 µg/min until the end of treatment.~The exenatide therapy will begin as soon as a blood glucose level is above 140 mg/dl will be measured. A of exenatide will be intravenously .~The treatment will be administrated during the first postoperative 48 hours in the intensive care unit or until intensive care unit discharge if this event occurs earlier.
Study NCT02432976 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin
Description: Insulin: Humalog (insulin lispro human analog). The insulin therapy will begin as soon as a blood glucose level is above 140 mg/dl will be measured.~The dose of insulin intravenously infused will be adapted to blood glucose measurements, following the insulin therapy protocol used in our department.~The insulin therapy protocol used in our department and prescribed as the benchmark treatment in the present study has been validated in a previous study. It has been derived from the protocol validated by Goldberg et al.
Study NCT06395194 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cardiac outcomes on treatment with valsartan
Description: Patients who already were on treatment, discontinued their previous antihypertensive medications when randomized to one of the trial's masked study arms (valsartan or amlodipine) without a run-in phase (rolled over). Valsartan treatment started at a dosage of 80 mg daily. If BP did not reach \<140/90 mmHg, the valsartan dose was doubled to 160 mg, and then hydrochlorothiazide (12.5 mg and 25 mg daily) and other antihypertensive drugs were added in sequential steps.
Study NCT02197325 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PICSO
Description: Pressure controlled Intermittent Coronary Pressure Occlusion
Study NCT06395194 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cardiac outcomes on treatment with amlodipine
Description: Patients who already were on treatment, discontinued their previous antihypertensive medications when randomized to one of the trial's masked study arms (valsartan or amlodipine) without a run-in phase (rolled over). Amlodipine treatment started at 5 mg daily. If BP did not reach \<140/90 mmHg, the amlodipine dose was doubled to 10 mg, and then hydrochlorothiazide (12.5 mg and 25 mg daily) and other antihypertensive drugs were added in sequential steps.
Study NCT02131363 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ingrowing Toenail Treatment Kit
Description: detailed in arm description
Study NCT02376777 — intervention group
Intervention type: OTHER
Intervention: Follow up
Description: each three months during one year of follow up, general practioners will entered health data in database (hemorrhagic events, changes of medication, biological data...)
Study NCT04757792 — intervention group
Intervention type: OTHER
Intervention: File inquiry
Description: Data extraction out of file registry
Study NCT01358344 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pantoprazole
Description: 40 mg delayed-release tablet administered orally in the morning of Days 1-7
Study NCT01358344 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCH 530348 (high percentage)
Description: 2.5 mg tablet containing \~46% active pharmaceutical ingredient (API) as free base (46+5%) administered orally on the morning of Day 5
Study NCT01358344 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCH 530348 (standard percentage)
Description: 2.5 mg tablet containing \~23% API as free base (STANDARD) administered orally on the morning of Day 5
Study NCT00080951 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Study NCT00080951 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Study NCT00080951 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Study NCT00080951 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Study NCT01935076 — intervention group
Intervention type: BEHAVIORAL
Intervention: Neonatal exposure to maternal obesity
Study NCT01111864 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: fortification with iron and micronutrients
Description: Iron 0 or 2.5 mg; Copper 0.34 mg; 30 µg Iodine; 7 µg Selenium; 2.5 mg Zinc; 100 µg Vitamin A; Vitamin D 5 µg; 5 mg Tocopherol Equivalent; 30 µg Vitamin K1; 10.5 mg Thiamine; 0.5 mg Riboflavin; 0.5 mg Pyridoxine; 90 µg Folic Acid Anhydrous; 6 mg Niacinamide; 60 mg Vitamin C; 0.9 µg Vitamin B12
Study NCT01111864 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: fortification with iron and micronutrients
Description: Iron 0 or 2.5 mg; Copper 0.34 mg; 30 µg Iodine; 7 µg Selenium; 2.5 mg Zinc; 100 µg Vitamin A; Vitamin D 5 µg; 5 mg Tocopherol Equivalent; 30 µg Vitamin K1; 10.5 mg Thiamine; 0.5 mg Riboflavin; 0.5 mg Pyridoxine; 90 µg Folic Acid Anhydrous; 6 mg Niacinamide; 60 mg Vitamin C; 0.9 µg Vitamin B12
Study NCT01111864 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sprinkles
Description: Daily 12.5mg Ferrous fumarate iron with microntrient is compared to no iron with micronutrients. Duration of intervention is 4 months, 80 infants will be inclulded.
Study NCT01111864 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Sprinkles
Description: Daily 12.5mg Ferrous fumarate iron with microntrient is compared to no iron with micronutrients. Duration of intervention is 4 months, 80 infants will be inclulded.
Study NCT02604420 — intervention group
Intervention type: DRUG
Intervention: eculizumab
Study NCT04320420 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adapted Physical Activity
Description: The APA program is defined in 3 stages:~STEP 1: during the initial chemotherapy over 3 months~* 3 supervised APA sessions/week on site:~  * two muscle strengthening sessions, stretching, flexibility in the gym~ * a cardio session (Nordic Walking: outdoors)~* at home: exercise book if the patient wishes~STEP 2: during hospitalization for the autograft, over 1 month:~* 2 sessions/week supervised by an APA engineer + exercise book and encouragement of individual work~* If the patient wishes, he can continue the exercises carried out with the APA engineer independently~STEP 3: after the transplant~* the first 3 months:~  * 2 supervised indoor sessions/week (muscle strengthening, stretching, flexibility),~ * 1-hour cardio session/week independently~* the following 3 months: 1 indoor session per week + independent exercises at home and walking or cycling sessions
Study NCT02810886 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-(HBED-CC)-PSMA
Description: 68Ga-PSMA-ligand intravenous administration duration is around one minute. Once the patient is injected, the tracer needs 60 minutes to be evenly distributed through the body. PET/CT images will then be performed.
Study NCT01507337 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: A single dose of 1 mg administered subcutaneously (under the skin)